Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for Clovis Oncology stock to perform well in the short-term.
Similarly, Will Clovis Oncology be bought?
Nothing has changed since our initial recommendation in January 2020 and the benefit/risk ration of this share is still excellent. With a stock price of around $5.80 and a market cap of $509 million, Clovis Oncology remains one of the top takeover target and buyout candidate for 2021.
What does Clovis Oncology do? Founded in 2009, Clovis Oncology (NASDAQ: CLVS) is a commercial stage biotechnology company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets.
Thereof, Why is Clvs stock dropping?
Biotechnology investors are familiar with Clovis Oncology (NASDAQ:CLVS). The company’s stock is beaten down (down over 90% from the 2017 high) after the company lost the PARP inhibitor race to competition like AstraZeneca (AZN) and sales of its PARP inhibitor Rubraca did not meet analyst expectations.
Who owns Clvs?
Top 10 Owners of Clovis Oncology Inc
| Stockholder | Stake | Shares owned |
|---|---|---|
| The Vanguard Group, Inc. | 6.90% | 9,820,571 |
| BlackRock Fund Advisors | 5.82% | 8,284,149 |
| Palo Alto Investors LP | 2.81% | 3,997,826 |
| Geode Capital Management LLC | 1.56% | 2,212,612 |
Should I invest in Clovis Oncology?
There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should « buy » Clovis Oncology stock. View analyst ratings for Clovis Oncology or view top-rated stocks.
Why did Clovis Oncology stock go Up?
Why Clovis Oncology Stock Skyrocketed 80% This Week
Shares of Clovis Oncology (NASDAQ: CLVS) jumped 80% this week, according to data from S&P Global Market Intelligence. Clovis’ big move didn’t come until Thursday, however, when the company announced positive data regarding its drug Rubraca (rucaparib).
Who founded Clovis Oncology?
Clovis Oncology is an American pharmaceutical company which mainly markets products for treatment in oncology. Clovis was founded in 2009 and is headquartered in Boulder, Colorado.
…
Clovis Oncology.
| Type | Public |
|---|---|
| Founder | Patrick Mahaffy |
| Headquarters | Boulder, Colorado , U.S. |
| Revenue | $165 Million(2020) |
| Number of employees | 429 |
Is Clovis Oncology a good company?
Clovis Oncology has an overall rating of 3.6 out of 5, based on over 35 reviews left anonymously by employees. 47% of employees would recommend working at Clovis Oncology to a friend and 35% have a positive outlook for the business. This rating has improved by 8% over the last 12 months.
What is the short interest on Clvs?
Clovis Oncology currently has a short interest ratio of 6.0. Learn More on Clovis Oncology’s short interest ratio.
When did Clovis Oncology go public?
In addition, the underwriters have a 30-day option to purchase up to an additional 1,500,000 shares of common stock from Clovis Oncology to cover over-allotments, if any. Shares of Clovis Oncology’s common stock will trade on the NASDAQ Global Select Market under the symbol « CLVS » beginning on November 16, 2011.
Who is the CEO of Clovis Oncology?
President/CEO/Co-Founder, Clovis Oncology Inc.
Is Clvs a shorted stock?
Short Shares Availability
This table shows the number of shares of US:CLVS available to be shorted at a leading prime brokerage. It is not the total number of shares available to short, nor is it the short interest.
How much is Clvs shorted?
Short Interest: CLVS (NASDAQ)
| Clovis Oncology Incorporated | $ 2.65 |
|---|---|
| CLVS (NASDAQ) | -0.14 |
Join TheMoney.co community and don’t forget to share this post !
